concentrations (MIC) susceptibility testing
). [1] [2] [3] These revised interpretive criteria were approved by the CLSI committee members after evaluation of the pharmacokinetic-pharmacodynamic properties of these agents, the distribution of MIC, and, unfortunately, limited data on clinical outcome.
For cephalosporins, the current CLSI Informational Supplements note that when using the new interpretive criteria, routine testing for extended-spectrum β-lactamases (ESBL) is no longer necessary before reporting results (e.g. it is no longer necessary to edit results for cephalo sporins, aztreonam, or penicillins from susceptible to resistant). [1] [2] These informational supplements did not change the interpretive criteria for cefepime and cefuroxime (parenteral). 1-2 They also emphasize that interpretive criteria for drugs with limited availability in many countries (i.e. moxalactam, cefonicid, cefamandole, and cefoperazone) were not evaluated. 2 3 Once laboratories implement these new interpretive criteria, MHT does not need to be performed other than for epidemiology and infection control purposes. 3 The consensus meeting agreed that there is no need to apply the revised interpretive criteria for cephalosporins and carbapenems to define susceptibility categories for Enterobacteriaceae for several reasons. First, the new ceftazidime (≤ 4 μg/mL) and the unchanged cefepime (≤ 8 μg/mL) susceptible breakpoints failed to identify many ESBLproducing E. coli, K. pneumoniae, and K. oxytoca (Figure) . [4] [5] Indications for the clinical use of cefepime or thirdgeneration cephalosporins for the treatment of infections caused by ESBL-producing E. coli and K. pneumoniae isolates with lower MICs (≤ 8 μg/mL for cefepime and ≤ 4 μg/ mL for ceftazidime) remain unclear. 2 Similarly, the clinical efficacy of carbapenems for the treatment of infections caused by isolates for which the carbapenem MIC or (Tables 2 and 3 ). [1] [2] [3] The consensus meeting concluded that owing to some subgroups of ESBL-producing isolates that remained susceptible to ceftazidime and cefepime defined by the CLSI 2010 breakpoints, confirmation testing of ESBL phenotypes may still be helpful in monitoring evolving epidemiology and to assist in early implementation of appropriate infection control measures. This situation is especially important in countries (e.g. Taiwan) with a high burden of infections caused by ESBL-producing Enterobacteriaceae. The decreased susceptibility to ertapenem of some Enterobacteriaceae isolates using the new criteria is alarming, particularly for ESBL-producing K. pneumoniae and E. cloacae. There is an urgent need to establish the local microbiological and clinical outcome data to support the necessity of implementing these new criteria in Taiwanese clinical microbiology laboratories and in clinical practice to ensure appropriate antimicrobial therapy in the management of infections due to Enterobacteriaceae.
